Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 5/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27364779 | 0.83 | BCHE (0.33) | BCHEADRB3ADRB2ADRB1ACHE | |
| SCHEMBL20698362 | 0.80 | — | — | |
| SCHEMBL12423880 | 0.79 | TSHR (0.43) | BCHEADRB3ADRB2ADRB1ACHE | |
| SCHEMBL8845694 | 0.79 | BCHE (0.31) | BCHEADRB3 | |
| SCHEMBL7775227 | 0.79 | — | — | |
| SCHEMBL7775279 | 0.79 | BCHE (0.31) | BCHEADRB3TSHR | |
| SCHEMBL12423948 | 0.79 | TSHR (0.43) | BCHEADRB3ADRB2ADRB1ACHE | |
| SCHEMBL5177835 | 0.78 | ADH1B (0.31) | ADH1BADH1CADH1ATSHRTDP1 | |
| SCHEMBL12039743 | 0.78 | ADH1B (0.31) | ADH1BADH1CADH1A | |
| SCHEMBL15442709 | 0.77 | BCHE (0.32) | BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357191-A1 | MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-11-09 | — | — | US | disclosed |
| WO-2023209086-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-02 | — | — | WO | disclosed |
| US-9676964-B1 | Visible light activated aqueous based self-decontaminating coating composition | LOMBARDI JOHN L (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| CN-101687988-A | Polybenzazole and polybenzazole precursor | TEIJIN ARAMID BV | 2010-03-31 | — | — | CN | disclosed |
| EP-0838508-B1 | Aqueous ink composition for use in an ink-jet printer | SEIKO EPSON CORP (JP) | 2001-08-29 | — | — | EP | disclosed |
| US-5871572-A | COLORANT, WATER, A WATER-SOLUBLE ORGANIC SOLVENT, AND PECTIC ACID | SEIKO EPSON CORPORATION (JP) | 1999-02-16 | — | — | US | disclosed |
| EP-0838508-A2 | Aqueous ink composition for use in an ink-jet printer | SEIKO EPSON CORPORATION (JP) | 1998-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | BCHE 3672/4885ADRB3 4527/4885ADRB2 4368/4885 |
| US-20230357191-A1 | MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | CFTR, SLC26A4, TMEM109 | BCHE 3452/4885ADRB3 356/4885ADRB2 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.